🎀💊 FDA APPROVES NEW BREAST CANCER PILL THAT CAN TARGET RESISTANCE BEFORE THE CANCER SHOWS PROGRESSION

This is the kind of medical news we LOVE reporting. Scientists may have found a new way to catch breast cancer trying to outsmart treatment and switch strategies before scans even show the disease getting worse.

The FDA has granted accelerated approval to Etcamah, also known as camizestrant, a once-daily oral medication developed by AstraZeneca for a specific group of adults living with advanced breast cancer. The approval was announced September 4, 2026.

And this isn't simply another cancer pill being added to the pharmacy shelf.

What makes this one particularly interesting is WHEN doctors may be able to use it.

🧬 THE CANCER CAN CHANGE. NOW DOCTORS CAN WATCH FOR THE CHANGE.

Etcamah is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors develop a mutation called ESR1 while they're receiving an aromatase inhibitor and a CDK4/6 inhibitor.

Okay, Lady Red translation because medical terminology will have you reading the same sentence six times:

Some breast cancers depend on estrogen signals to grow. Treatments can block that pathway and work well for a while.

But cancer can be a sneaky little heaux.

Over time, some tumors develop an ESR1 mutation that can help them become resistant to certain hormone treatments.

According to the FDA, fewer than 5% of patients have this mutation when HR-positive metastatic breast cancer is initially diagnosed. But after the cancer progresses during treatment with an aromatase inhibitor, the mutation can be found in nearly 40% of patients. 

In other words, the treatment may still be standing at the front door while the cancer is trying to figure out how to climb through a window.

Etcamah gives doctors another way to respond.

🩸 AND HERE'S THE REALLY BIG PART: A BLOOD TEST CAN FIND THE MUTATION

Doctors don't necessarily have to wait until a tumor grows enough to show progression on an imaging scan.

Tiny pieces of tumor DNA can circulate in a patient's bloodstream. This is called circulating tumor DNA, or ctDNA.

A blood test can detect the ESR1 mutation, potentially revealing that the cancer is developing treatment resistance at the molecular level.

The FDA also authorized the Guardant360 CDx blood test as the companion diagnostic used to identify eligible patients.

And THIS is what makes the approval historic.

According to the FDA, this is the first FDA approval of a cancer therapy guided by detection of a resistance mutation in circulating tumor DNA before imaging shows that the disease is progressing. 

Now THAT is some science-sciencing. 🧬👏🏾

Instead of:

“The cancer got worse. Let's change treatment.”

The strategy can potentially become:

“We're seeing evidence that this cancer is learning how to resist the treatment. Let's change course now.”

That's a major difference.

📊 AND THE CLINICAL TRIAL NUMBERS GOT ATTENTION

The approval is based on results from the Phase III SERENA-6 trial.

Patients whose emerging ESR1 mutation was detected switched from their aromatase inhibitor to Etcamah while continuing a CDK4/6 inhibitor.

The estimated median time before the cancer progressed was:

16 months with Etcamah + a CDK4/6 inhibitor

compared with

9.2 months for patients continuing an aromatase inhibitor + a CDK4/6 inhibitor.

AstraZeneca reported that the combination reduced the risk of disease progression or death by 56% in the trial analysis.

That's roughly 6.8 additional months of median progression-free survival in this particular study population.

And when you're talking about metastatic cancer?

Months matter.

⚠️ BUT THIS IS IMPORTANT: THIS IS NOT A CURE FOR BREAST CANCER

Let's make sure social media doesn't grab the headline and run clear across the parking lot with it.

Etcamah is not approved for every type or stage of breast cancer, and the FDA did not announce a cure.

This approval specifically concerns certain adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer who develop an ESR1 mutation during particular treatment. 

It's also an accelerated approval, which means additional evidence is still required to confirm the long-term clinical benefit of switching treatment when the mutation appears in the blood before conventional disease progression is detected.

Etcamah also has important safety considerations. Its prescribing information includes a boxed warning concerning the risk of serious abnormal heart rhythms when combined with certain medications, and patients require cardiac monitoring.

So this is absolutely a doctor-and-patient treatment decision, not something anybody should be diagnosing themselves for after reading an article.

💗 LADY RED'S TAKE

THIS is the type of breakthrough I want filling up my timeline.

Because cancer treatment isn't only about developing stronger weapons.

Sometimes it's about figuring out what the cancer is planning before it makes its next move.

A simple blood sample containing microscopic pieces of tumor DNA can potentially tell doctors:

“This treatment is starting to lose its grip.”

And now, for this particular group of breast cancer patients, doctors have another FDA-approved treatment strategy available before imaging necessarily shows progression.

Cancer tried to change the combination.

Science started reading over its shoulder. 🧬💗

And THAT deserves a BOOM. 💥

730 BOOM RADIO

IT HITS DIFFERENT. EVERY TIME. BOOM! 💥